RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition

Abstract Background The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess in this context the role of mTORC2, a signaling complex defined by the...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Luca Ponzone, Valentina Audrito, Claudia Landi, Enrico Moiso, Chiara Levra Levron, Sara Ferrua, Aurora Savino, Nicoletta Vitale, Massimiliano Gasparrini, Lidia Avalle, Lorenza Vantaggiato, Enxhi Shaba, Beatrice Tassone, Stefania Saoncella, Francesca Orso, Daniele Viavattene, Eleonora Marina, Irene Fiorilla, Giulia Burrone, Youssef Abili, Fiorella Altruda, Luca Bini, Silvia Deaglio, Paola Defilippi, Alessio Menga, Valeria Poli, Paolo Ettore Porporato, Paolo Provero, Nadia Raffaelli, Chiara Riganti, Daniela Taverna, Federica Cavallo, Enzo Calautti
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2024-05-01
Saila:	Molecular Cancer
Gaiak:	mTORC2 RICTOR NAMPT Drug resistance Targeted therapy BRAFV600E melanoma
Sarrera elektronikoa:	https://doi.org/10.1186/s12943-024-02010-1
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!